Category: Zimmer Holdings
More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.
Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic, Covidien name peripherals biz transition team; Medtronic is still in on Covidien buyout; The Street cheers changes to the Medtronic, Covidien deal; Zimmer adds Harvard spinout Etex Corp.; EU to extend Zimmer, Biomet probe
European anti-trust regulators are extending their probe into the proposed $13 billion merger of orthopedics rivals Zimmer and Biomet.
UPDATED Oct. 2, 2013, with comment from Zimmer.
Zimmer acquires Etex Corp. and its line of bone biomaterials for an unspecified amount.
Zimmer (NYSE:ZMH) said yesterday that it paid an unspecified amount for Etex Corp. and the bone biomaterials it's developing in Cambridge, Mass.
Zimmer and Biomet provide updates following the 2nd in a series of "Integration Summits" where company leadership is fleshing out the details of their $13 billion merger.
Leadership at Zimmer (NYSE:ZMH) and Biomet have been on merger overdrive in recent weeks, holding summits and hosting presentations as the companies navigate the tricky business of a $13 billion merger.
MiMedx licenses its dHACM allografts to orthopedics giant Zimmer non-exclusively on a private label basis.
Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range